Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial
| Autor: | T. S. Marshall, Sergio Forero-Schwanhaeuser, Michael D. Vardy, J. D. Wegenke, W. He, H D Mitcheson, T.-A. Samuels |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male Quinuclidines medicine.medical_specialty Placebo-controlled study Muscarinic Antagonists urologic and male genital diseases Placebo Young Adult Double-Blind Method Quality of life Tetrahydroisoquinolines Internal medicine medicine Humans Nocturia Adverse effect Aged Aged 80 and over Analysis of Variance Solifenacin Urinary Bladder Overactive business.industry Solifenacin Succinate General Medicine Middle Aged medicine.disease female genital diseases and pregnancy complications humanities The Overactive Bladder Questionnaire Surgery Treatment Outcome Overactive bladder Quality of Life Female medicine.symptom business medicine.drug |
| Zdroj: | International Journal of Clinical Practice. 63:1702-1714 |
| ISSN: | 1742-1241 1368-5031 |
| DOI: | 10.1111/j.1742-1241.2009.02209.x |
| Popis: | Summary Aim: The aim of this study was to evaluate the efficacy of solifenacin on symptom bother using the Overactive Bladder Questionnaire (OAB-q). Methods: In VIBRANT, a double-blind, US-based trial, patients with OAB for ≥ 3 months received flexibly dosed solifenacin or placebo for 12 weeks. At baseline and 4-week intervals, patients completed the OAB-q [symptom bother and health-related quality of life (HRQL) scales] and 3-day bladder diaries; other patient-reported outcome measures were also assessed at baseline and week 12. The primary efficacy end-point was the change from baseline to end of treatment (EOT) on the OAB-q Symptom Bother scale. Adverse events (AEs) were monitored. Results: At EOT, solifenacin (n = 377) vs. placebo (n = 374) significantly improved mean symptom bother (−29.9 vs. −20.4, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|